Experimental HIV vaccine regimen safe but ineffective, NIH study finds

Another Major HIV Vaccine Trial Fails

THURSDAY, Jan. 19, 2023 (HealthDay News) -- In yet another setback for the future of HIV prevention, the only HIV vaccine in a late-stage trial has failed, study leaders announced

Another major HIV vaccine trial fails

The Mosaico trial was halted early after its vaccine failed to prevent HIV in men who have sex with men and transgender people in the Americas and Europe.

Another HIV vaccine fails to provide protection in discontinued trial

Janssen on Wednesday announced it has stopped the phase 3 Mosaico trial because the investigational HIV vaccine regimen it was testing was not effective in preventing HIV infection compared with placebo.

U.S. experimental HIV vaccine regimen safe but ineffective: study

LOS ANGELES, Jan. 18 (Xinhua) -- A U.S. investigational HIV vaccine regimen was safe but did not provide protection against HIV acquisition, according to a release of the U.S. National Institute of Health (NIH) on Wednesday. Read full story

Experimental HIV vaccine regimen safe but ineffective

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined. The HPX3002/HVTN 706, or 'Mosaico,' Phase 3 clinical trial began in 2019 and involved 3,900 volunteers ages 18 to 60 years in Europe, North America and South America. Based on the DSMB's recommendation, the…

J&J’s HIV vaccine fails Phase 3 clinical trial

Johnson & Johnson’s experimental HIV vaccine is safe but not effective, and the late-stage study will be discontinued as a result of that finding, federal...